AU2003274649A1 - Diagnostic markers for therapeutic treatment - Google Patents

Diagnostic markers for therapeutic treatment

Info

Publication number
AU2003274649A1
AU2003274649A1 AU2003274649A AU2003274649A AU2003274649A1 AU 2003274649 A1 AU2003274649 A1 AU 2003274649A1 AU 2003274649 A AU2003274649 A AU 2003274649A AU 2003274649 A AU2003274649 A AU 2003274649A AU 2003274649 A1 AU2003274649 A1 AU 2003274649A1
Authority
AU
Australia
Prior art keywords
therapeutic treatment
diagnostic markers
markers
diagnostic
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003274649A
Other versions
AU2003274649A8 (en
Inventor
Sara Bar Yehuda
Pnina Fishman
Lea Madi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of AU2003274649A8 publication Critical patent/AU2003274649A8/en
Publication of AU2003274649A1 publication Critical patent/AU2003274649A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003274649A 2002-10-21 2003-10-21 Diagnostic markers for therapeutic treatment Abandoned AU2003274649A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41959502P 2002-10-21 2002-10-21
US60/419,595 2002-10-21
PCT/IL2003/000857 WO2004036215A2 (en) 2002-10-21 2003-10-21 Diagnostic markers for therapeutic treatment

Publications (2)

Publication Number Publication Date
AU2003274649A8 AU2003274649A8 (en) 2004-05-04
AU2003274649A1 true AU2003274649A1 (en) 2004-05-04

Family

ID=32108110

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003274649A Abandoned AU2003274649A1 (en) 2002-10-21 2003-10-21 Diagnostic markers for therapeutic treatment

Country Status (4)

Country Link
EP (1) EP1554574A2 (en)
JP (1) JP2006503564A (en)
AU (1) AU2003274649A1 (en)
WO (1) WO2004036215A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766060A4 (en) * 2004-05-14 2007-11-28 King Pharmaceuticals Res & Dev Methods of diagnosing and prognosticating solid tumors and melanoma
WO2006059328A1 (en) * 2004-12-02 2006-06-08 Can-Fite Biopharma Ltd. Treatment of inflammation
TWI443337B (en) * 2008-10-10 2014-07-01 Ct Hospitalier Universitaire Sainte Justine Methods for the classification and diagnosis of scoliosis
JP5689061B2 (en) * 2009-09-01 2015-03-25 タカラバイオ株式会社 Composition for reverse transcription polymerase chain reaction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses

Also Published As

Publication number Publication date
WO2004036215A3 (en) 2004-09-10
AU2003274649A8 (en) 2004-05-04
WO2004036215A2 (en) 2004-04-29
JP2006503564A (en) 2006-02-02
WO2004036215A9 (en) 2004-08-05
EP1554574A2 (en) 2005-07-20

Similar Documents

Publication Publication Date Title
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
AU2003286552A1 (en) Implantable medical device for improved placement
AU2003300791A1 (en) Combination therapy for the treatment of pain
GB0201674D0 (en) Medical treatment
HK1078784A1 (en) Therapeutic treatment
AU2003294318A1 (en) Therapeutic bioconjugates
GB0223367D0 (en) Therapeutic treatment
AU2003221042A1 (en) Preventive or therapeutic agent for kidney disease
GB0218879D0 (en) Medical treatment
AU2003247005A1 (en) Therapy combination
AU2003255372A1 (en) Medical device
AU2003270852A1 (en) Patient positioning system
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
AU2003215150A1 (en) Therapeutic compounds
AU2003267668A1 (en) Medical apparatus
AU2003241154A1 (en) Navigator-robot for surgical procedures
PL397023A1 (en) Therapeutic agent for AIDS treatment
GB0210464D0 (en) Therapeutic treatment
AU2003274649A1 (en) Diagnostic markers for therapeutic treatment
AU2002226683A1 (en) Complex therapy for tissue regeneration
AU2003256112A1 (en) Patient bed
AU2003242991A1 (en) Apparatus for therapeutic treatments
AU2003213349A1 (en) Therapeutic agent for pain
AU2003207520A1 (en) Treatment for intracranial tumors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase